Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CDH20
REST API REST API
Homo sapiens
CDH20 is differentially expressed in 102 experiments: 54 organism parts: trigeminal ganglion, blood, ... (52 more);, 71 disease states: normal, breast carcinoma, ... (69 more);, 19 cell types 80 cell lines 10 compound treatments and 53 other conditions.
Synonyms CDH7L3, Cdh7
Orthologs CAD20_CHICK (Gallus gallus)   Cdh20 (Mus musculus)   E1BAM8_BOVIN (Bos taurus)   Cdh20 (Rattus norvegicus)   cdh20 (Xenopus laevis)   Q6JDM3_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, cell-cell adhesion, membrane, homophilic cell adhesion, integral to membrane, calcium ion binding
InterPro Term Cadherin, Cadherin_cytoplasmic-dom
UniProt Accession Q9HBT6, Q8N9J3
Search EB-eye ENSG00000101542
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-GEOD-6573, E-MTAB-24, E-MTAB-25, E-TABM-145, ... (13 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-MTAB-37, E-GEOD-5823, E-GEOD-19639, E-TABM-420, ... (9 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-5823, E-GEOD-19639, E-GEOD-20081
ssMCF7
1
E-GEOD-5258
293t-tva
1
E-MTAB-62
SJSA1
1
E-MTAB-37
BE2C
1
E-MTAB-37
MDAMB175VII
1
E-MTAB-37
74 more value(s).


Cell type

studied in E-GEOD-10797, E-AFMX-5, E-GEOD-6053, E-GEOD-3920, E-MEXP-669, ... (15 experiments)

Factor Value U/D Experiments
stromal cell
2
E-GEOD-10797, E-MEXP-2034
neuroblastoma cell
1
E-MEXP-669
mesenchymal stem cell
1
E-GEOD-9894
naive B cell
1
E-TABM-702
CD34+
1
1
E-AFMX-5
1
1
E-TABM-145
13 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-19743, E-GEOD-6872, E-GEOD-15960, E-MEXP-1507, ... (22 experiments)

Factor Value U/D Experiments
glioblastoma
2
E-GEOD-4412, E-GEOD-4290
acute erythroid leukemia
1
E-GEOD-1729
prostate carcinoma
1
E-MTAB-62
FKRP mutation
1
E-GEOD-3307
colorectal adenocarcinoma
1
E-MTAB-37
adjacent normal skin
1
E-GEOD-15101
65 more value(s).


Compound treatment

studied in E-MEXP-1269, E-GEOD-5258, E-GEOD-3284, E-GEOD-5824, E-MEXP-941, ... (7 experiments)

Factor Value U/D Experiments
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
control
25
1
E-GEOD-3284
none
1
E-GEOD-5824
glucose
1
E-MEXP-941
glutamine
1
1
E-MEXP-941
vanadium pentoxide
1
E-GEOD-5339
4 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Clinical history
studied in E-GEOD-19743

Clinical info
studied in E-GEOD-19743, E-MTAB-37

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-MTAB-62

Disease staging
studied in E-GEOD-19743

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genotype
studied in E-GEOD-17476, E-TABM-601

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-20504, E-MEXP-1103

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-2069, E-TABM-666, E-GEOD-19519, ... (16 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Localisation of metastases
studied in E-GEOD-22541

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-5820

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-19246, E-GEOD-1343

RNAi
studied in E-MEXP-101, E-MEXP-548

Sample preparation
studied in E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Subtype
studied in E-GEOD-24283

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-16837, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271

Vehicle
studied in E-GEOD-5258

Processing time: 0.59 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM